2 completed, 2 terminated. 3 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 3 | Completed 2, Terminated 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Medexus Pharma, Inc.: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Treosulfan-Based Versus Clofarabine-Based Conditioning Before Donor Hematopoietic Stem Cell Transplant for the Treatment of Myelodysplastic Syndromes or Acute Myeloid Leukemia Clofarabine, Fludarabine, Hematopoietic Cell Transplantation - Acute Myeloid Leukemia, Myelodysplastic Syndrome | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 23 | 2023-08-11 | 2026-08-06 |
| Evaluation of a Recombinant Factor IX Product, APVO101, in Previously-Treated Pediatric Patients With Hemophilia B APVO101 - Hemophilia B | Phase 3 | Completed | Medexus Pharma, Inc. | 21 | 2020-01-16 | 2024-05-16 |
| Study of Recombinant Factor IX Product, IB1001, in Previously Treated Pediatric Subjects With Hemophilia B IB1001 - Hemophilia B | Phase 3 | Terminated | Medexus Pharma, Inc. | 9 | 2010-11-01 | 2021-03-15 |
| Study of Recombinant Factor IX Product, IB1001, in Subjects With Hemophilia B IB1001, nonacog alfa - Hemophilia B | Phase 2 / Phase 3 | Completed | Medexus Pharma, Inc. | 77 | 2009-01-01 | 2021-04-06 |
Hemophilia B (3) · Leukemia, Myeloid, Acute (1) · Myelodysplastic Syndromes (1)
IB1001 (3) · Clofarabine (1) · Factor IX (1) · Hematopoietic Stem Cell Transplantation (1) · Spinal Puncture (1) · Stem Cell Transplantation (1) · Whole-Body Irradiation (1) · fludarabine (1) · treosulfan (1)
United States (3) · India (2) · United Kingdom (2) · Brazil (1) · France (1) · Georgia (1) · Israel (1) · Italy (1) · Moldova (1) · Poland (1) · South Africa (1) · Turkey (Türkiye) (1) · Ukraine (1)
Khaled Mohamed (1) · Phuong Vo (1)